Direkt zum Inhalt
Merck
  • Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.

Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.

European journal of medicinal chemistry (2011-02-19)
Hyun You, Hyung-Seop Youn, Isak Im, Man-Ho Bae, Sang-Kook Lee, Hyojin Ko, Soo Hyun Eom, Yong-Chul Kim
ZUSAMMENFASSUNG

NAmPRTase (PBEF/Visfatin) plays a pivotal role in the salvage pathway of NAD(+) biosynthesis. NAmPRTase has been an attractive target for anti-cancer agents that induce apoptosis of tumor cells via a declining plasma NAD(+) level. In this report, a series of structural analogs of FK866 (1), a known NAmPRTase inhibitor, was synthesized and tested for inhibitory activities against the proliferation of cancer cells and human NAmPRTase. Among them, compound 7 showed similar anti-cancer and enzyme inhibitory activities to compound 1. Further investigation of compound 7 with X-ray analysis revealed a co-crystal structure in complex with human NAmPRTase, suggesting that Asp219 in the active site of the enzyme could contribute to an additional interaction with the pyrrole nitrogen of compound 7.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
4-Piperidinbuttersäure, 97%